// App-Quantinova.ai

4070 : A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP).

Researchers

Presenter

  • Sandrine J. Faivre

Principal Investigators

  • Armando Santoro

  • Edward Gane

  • Robin Kate Kelley

  • I Ollivier Hourmand

  • Eric Assenat

  • Ivelina Gueorguieva

  • Ann Cleverly

  • Durisala Desaiah

  • Michael M. F. Lahn

  • Eric Raymond

  • Karim A. Benhadji

  • Gianluigi Giannelli

Medical Centers

  • Service d'Oncologie Medicale, Clichy, France

  • Humanitas Cancer Center, Humanitas Clinical and Research Center, and Humanitas University, Rozzano, Italy

  • Auckland City Hospital, Auckland, New Zealand

  • University of California, San Francisco, San Francisco, CA

  • Service d'Hepatogastroenterologie, C.H.U. Cote de Nacre, Caen, France

  • Department of Medical Oncology, Hopital Saint Eloi, Montpelier, France

  • Eli Lilly and Company, Erl Wood, United Kingdom

  • Eli Lilly and Company, Indianapolis, IN

  • CHUV, Lausanne, Switzerland

  • Lilly France, Paris, France

  • Internal Medicine, University Bari Medical School, Bari, Italy

Locations

  • Italy

  • United Kingdom

  • Switzerland

  • United States

  • France

  • New Zealand

Companies

  • EMB Statistical Solu

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Alpha-fetoprotein

  • Cadherin 1

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • LY2157299

  • Sorafenib

Outcome

  • Positive

Study Design

  • Pharmacokinetics

Phase

  • II

Study Id's

  • NCT01246986

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved